Soluble Fas level and cancer mortality: Findings from a nested case-control study within a large-scale prospective study

International Journal of Cancer

Volumn 123, Issue 8, 2008, Pages 1913-1916

  Tamakoshi, Akiko ^a   Nakachi, Kei ^b   Ito, Yoshinori ^c   Lin, Yingsong ^a   Yagyu, Kiyoko ^a   Kikuchi, Shogo ^a   Watanabe, Yoshiyuki ^d   Inaba, Yutaka ^e   Tajima, Kazuo ^f  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e JISSEN WOMEN'S UNIVERSITY   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cancer; Cohort study; Nested case control study; Soluble Fas

Indexed keywords

FAS ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANTIGENS, CD95; CASE-CONTROL STUDIES; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 51949100879     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23731     Document Type: Article

References (16)

1. Mizutani Y, Yoshida O, Bonavida B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J Urology 1998;160:571-6.
2. Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res 1999;5:3529-33.
3. Hefler L, Mayerhofer K, Nardi A, Reinthaller A, Kainz C, Tempfer C. Serum soluble Fas levels in ovarian cancer. Obstet Gynecol 2000;96:65-9.
4. Nonomura N, Nishimura K, Ono Y, Fukui T, Harada Y, Takaha N, Takahara S, Okuyama A. Soluble Fas in serum from patients with renal cell carcinoma. Urology 2000;55:151-5.
5. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 2001;7:1282-6.
6. Puiu L, Petrakou E, Apostolidou A, Athanassiadou A, Psiouri L, Papachatzopoulou A, Gorgoulis V, Kotsinas A, Tzoracoeleftherakis E, Maniatis G, Voutsinas G. Lack of Fas (APO-1/CD95) gene structural alterations or transcript variant ratio changes in breast cancer. Cancer Lett 2003;194:91-7.
7. Niitsu N, Sasaki K, Umeda M. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Leukemia 1999;13:1434-410.
8. Akhmedkhanov A, Lundin E, Guller S, Lukanova A, Micheli A, Ma Y, Afanasyeva Y, Zeleniuch-Jacquotte A, Krogh V, Lenner P, Muti P, Rinaldi S, et al. Circulating soluble Fas levels and risk of ovarian cancer. BMC Cancer 2003;3:33.
9. Ohno Y, Tamakoshi A, JACC Study Group. Japan collaboraetive cohort study for evaluation of cancer risk sponsored by Monbusho (JACC Study). J Epidemiol 2001;11:144-50.
10. Tamakoshi A, Yoshimura T, Inaba Y, Ito Y, Watanabe Y, Fukuda K, Iso H, JACC Study Group. Profile of the JACC Study. J Epidemiol 2005;15:S4-S8.
11. Ito Y, Nakachi K, Imai K, Hashimoto S, Watanabe Y, Inaba Y, Tamakoshi A, Yoshimura T, JACC Study Group. Stability of frozen serum levels of insulin-like growth factor-I, insulin-like growth factor-II, insulin-like growth factor binding protein-3, transforming growth factor beta, soluble Fas, and superoxide dismutase activity for the JACC study. J Epidemiol 2005;15:S67-S73.
12. Konno R, Takano T, Sato S, Yajima A. Serum soluble Fas level as a prognostic factor in patients with gynecological malignancies. Clin Cancer Res 2000;6:3576-80.
13. Jodo S, Kobayashi S, Nakajima Y, Matsunaga T, Nakayama N, Ogura N, Kayagaki N, Okumura K, Koike T. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol 1998;112:166-71.
14. Pignataro L, Arisi E, Sambataro G, Corsi MM. Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment. J Surg Oncol 2003;83:112-5.
15. Holdenrieder S, Stieber P. Apoptotic markers in cancer. Clin Biochem 2004;37:605-17.
16. Feldkamp J, Pascher E, Schott M, Goretzki P, Seissler J, Scherbaum WA. Soluble Fas is increased in hyperthyroidism independent of the underlying thyroid disease. J Clin Endocrinol Metab 2001;86:4250-3.